Vimarsana
Biggest News Aggregation in the World

Flow Release News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Flow Release. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Flow Release Today - Breaking & Trending Today

In a recent study, biodegradable sodium alginate–lignin (SA-L) blend formulations at different SA/L ratios were developed as low-cost coating material for highly efficient slow-release di-ammonium phosphate (DAP) fertiliser. - Vimarsana News

In a recent study, biodegradable sodium alginate–lignin (SA-L) blend formulations at different SA/L ratios were developed as low-cost coating material for highly efficient slow-release di-ammonium phosphate (DAP) fertiliser.

Published: October 14, 2022

In a recent study, biodegradable sodium alginate–lignin (SA-L) blend formulations at different SA/L ratios were developed as low-cost coating material for highly efficient slow-release di-ammonium phosphate (DAP) fertiliser.

Source: european-coatings.com
Related Topics:
Journal Of Coatings TechnologyCoatings TechnologyOdium Alginate Lignin Sal BlendFlow ReleaseI Ammonium Phosphate Fertiliser
Novo Seeds Portfolio Company NMD Pharma Reports Positive Top-Line Phase I/IIa Data in Myasthenia Gravis | Small Molecules - Vimarsana News

Novo Seeds Portfolio Company NMD Pharma Reports Positive Top-Line Phase I/IIa Data in Myasthenia Gravis | Small Molecules

Published: October 12, 2022

Novo Seeds Portfolio Company NMD Pharma Reports Positive Top-Line Phase I/IIa Data in Myasthenia Gravis

Source: pipelinereview.com
Related Topics:
Morten GraugaardLundbeckfonden BiocapitalNovo NordiskThomas Holm PedersenNovo GroupDrug AdministrationI Novo HoldingsInternational Clinical Trials RegistryCentre For Human Drug ResearchNovo Seeds Portfolio CompanyNovo Nordisk FoundationRoche Venture FundNovo HoldingsAarhus UniversityReports Positive Top Line PhaseMyasthenia GravisDenmarki OctoberBoard DirectorHolm PedersenChief Executive OfficerQuantitative Myasthenia Gravis ScoreHuman Drug ResearchSmall MoleculeNew Chemical EntityDrug Delivery
Kupando Raises €13 Million in Series A Funding Round | Small Molecules - Vimarsana News

Kupando Raises €13 Million in Series A Funding Round | Small Molecules

Published: September 27, 2022

Kupando Raises €13 Million in Series A Funding Round

Source: pipelinereview.com
Related Topics:
Pierre MorgonJohanna HolldackKazuhiko NonomuraWolfram NothaftThomas KrauseBrandenburg Kapital GmbBrandenburg KapitalLandes BrandenburgUniversity Of California San DiegoFund InvestorsMinistry For Economic AffairsGrowth FundBrandenburg Ministry Of EconomicsDennis Carson LaboratoryEuropean Fund For Regional DevelopmentKupando RaisesFunding RoundRemiges VenturesLifecare PartnersVentura Biomed InvestorsGermanyi SeptemberPhd PrincipalKupando BoardDeputy ChairmanGerhard Ries
Novartis Scemblix®, with novel mechanism of action, approved by the European Commission for adult patients with chronic myeloid leukemia | Small Molecules - Vimarsana News

Novartis Scemblix®, with novel mechanism of action, approved by the European Commission for adult patients with chronic myeloid leukemia | Small Molecules

Published: August 30, 2022

Novartis Scemblix®, with novel mechanism of action, approved by the European Commission for adult patients with chronic myeloid leukemia

Source: pipelinereview.com
Related Topics:
United StatesUnited KingdomEast HanoverNovartis ScemblixHaseeb AhmadAndreas HochhausOncology At Jena University HospitalAmerican Society For Clinical OncologyEuropean Hematology AssociationEuropean CommissionHead Of The Department HematologyApproval ProgramEuropean UnionEuropean Medicines AgencyNovartis Pharmaceuticals CorpCommittee For Medicinal Products Human UseSwitzerlandi AugustMedical OncologyJena University HospitalMedicinal ProductsHuman UseAmerican SocietyClinical OncologyEurope Innovative MedicinesAccelerated Approval Program
European Commission approves Oncopeptides' Pepaxti for the treatment of patients with relapsed refractory multiple myeloma | Small Molecules - Vimarsana News

European Commission approves Oncopeptides' Pepaxti for the treatment of patients with relapsed refractory multiple myeloma | Small Molecules

Published: August 18, 2022

European Commission approves Oncopeptides' Pepaxti for the treatment of patients with relapsed refractory multiple myeloma

Source: pipelinereview.com
Related Topics:
United KingdomOncopeptides PepaxtiRolf GulliksenJakob LindbergOncopeptide PepaxtiEuropean CommissionGlobal Head Of Corporate CommunicationsSwedeni AugustNasdaq StockholmEuropean Economic AreaGlobal HeadCorporate CommunicationsMultiple MyelomaMid CapSmall MoleculeNew Chemical EntityDrug DeliveryFlow Release